TOKYO -- More than 90 pct of patients receiving Lecanemab, an Alzheimer's drug, in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers in the country said.
Editor-in-Chief: LE THE CHU
Publication permit 1332/BTTTT-PTTH&TTĐT, granted by the Ministry of Information and Communications of
the Socialist Republic of Vietnam
Advertise with Us | Contact Us
Hotline: 0918.033.133
© All rights are reserved by Tuoi Tre/Tuoi Tre News. Content may not be republished, except with the prior written permission of Tuoi Tre/Tuoi Tre News.
Please enter Display Name
Please enter Email
Email Invalid Format
Please enter Email
Email Invalid Format
Incorrect password.
Incorrect login information.
Account locked, please contact administrator.
An error occurred. Please try again later.
